Protocol No
LOXO-J5M-OX-JOXA
Staff Member
Hui-Zi Chen
Phase
I
Summary
This research study is being done to test the safety of an investigational treatment called LY4050784. All patients, including you, will be receiving LY4050784 during your participation in this study. LY4050784 is an investigational (or experimental) drug, taken orally, that targets a gene called SMARCA2/BRM, and may treat certain cancers. LY4050784 will be explored in patients with solid tumors that have a particular genetic abnormality (called an alteration or mutation) of a gene called SMARCA4 and/or BRG1, which may make the cancer cells susceptible to this
treatment.
Objective
An Open-label, Multicenter Study of LY4050784 in Advanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer,
Stomach,
Prostate,
Breast Cancers,
Other Skin,
Lip, Oral Cavity and Pharynx,
Larynx,
Ovary,
Head and Neck Cancers,
Thoracic Cancers,
Sarcoma,
Other Urologic,
Pancreas/Liver,
Cervix,
Gynecologic Cancers,
Esophagus,
Melanoma, Skin,
Bladder,
Gastrointestinal Cancers,
Prostate and Urologic Cancers,
Early Phase/Multiple Disease Site Cancers,
Skin Cancers
ClinicalTrials.gov